Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
10
2021
revised:
18
02
2022
accepted:
08
03
2022
entrez:
26
4
2022
pubmed:
27
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
While breast cancer and its treatments may affect cognition, the longitudinal trajectories of cognition among those receiving differing cancer treatment types remain poorly understood. Prior research suggests hippocampal-prefrontal cortex network integrity may influence cognition, although how this network predicts performance over time remains unclear. We conducted a prospective trial including 69 patients with early-stage breast cancer receiving adjuvant therapy and 12 controls. Longitudinal cognitive testing was conducted at four visits: pretreatment-baseline, 6-7 months, 14-15 months, and 23-24 months. Cognitive composite scores of episodic memory, executive functioning, and processing speed were assessed at each timepoint. Baseline structural MRI was obtained in a subset of these participants, and hippocampal and prefrontal cortex regional volumes were extracted. Longitudinal linear mixed modeling revealed significant group by time interactions on memory performance, controlling for age and education. Post hoc analyses revealed this effect was driven by patients treated with chemotherapy or chemotherapy plus hormone therapy, who demonstrated the least improvement in memory scores over time. Treatment group did not significantly influence the relationship between time and processing speed or executive functioning. Neither pretreatment hippocampal nor prefrontal volume differed between groups, and there were no significant group by time by baseline regional volume effects on cognition. Patients with early-stage breast cancer treated with chemotherapy or chemotherapy plus hormone therapy benefit less from practice effects seen in healthy controls on memory tests. Loss of longitudinal practice effect may be a new and clinically relevant measure for capturing patients' experience of cognitive difficulties after treatment.
Sections du résumé
Background
UNASSIGNED
While breast cancer and its treatments may affect cognition, the longitudinal trajectories of cognition among those receiving differing cancer treatment types remain poorly understood. Prior research suggests hippocampal-prefrontal cortex network integrity may influence cognition, although how this network predicts performance over time remains unclear.
Methods
UNASSIGNED
We conducted a prospective trial including 69 patients with early-stage breast cancer receiving adjuvant therapy and 12 controls. Longitudinal cognitive testing was conducted at four visits: pretreatment-baseline, 6-7 months, 14-15 months, and 23-24 months. Cognitive composite scores of episodic memory, executive functioning, and processing speed were assessed at each timepoint. Baseline structural MRI was obtained in a subset of these participants, and hippocampal and prefrontal cortex regional volumes were extracted.
Results
UNASSIGNED
Longitudinal linear mixed modeling revealed significant group by time interactions on memory performance, controlling for age and education. Post hoc analyses revealed this effect was driven by patients treated with chemotherapy or chemotherapy plus hormone therapy, who demonstrated the least improvement in memory scores over time. Treatment group did not significantly influence the relationship between time and processing speed or executive functioning. Neither pretreatment hippocampal nor prefrontal volume differed between groups, and there were no significant group by time by baseline regional volume effects on cognition.
Conclusion
UNASSIGNED
Patients with early-stage breast cancer treated with chemotherapy or chemotherapy plus hormone therapy benefit less from practice effects seen in healthy controls on memory tests. Loss of longitudinal practice effect may be a new and clinically relevant measure for capturing patients' experience of cognitive difficulties after treatment.
Identifiants
pubmed: 35469310
doi: 10.1155/2022/5899728
pmc: PMC9034940
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5899728Informations de copyright
Copyright © 2022 Alexandra C. Apple et al.
Déclaration de conflit d'intérêts
Authors declare no conflicts of interest.
Références
Lancet Neurol. 2012 Nov;11(11):1006-12
pubmed: 23079557
J Clin Oncol. 2012 Oct 20;30(30):3675-86
pubmed: 23008308
J Clin Oncol. 2012 Oct 10;30(29):3578-87
pubmed: 22927526
Behav Brain Res. 2010 Mar 5;207(2):265-72
pubmed: 19840821
J Clin Exp Neuropsychol. 2012;34(5):543-60
pubmed: 22380580
Eur J Neurosci. 2012 Dec;36(11):3521-30
pubmed: 23039863
Neurobiol Aging. 2019 Nov;83:124-129
pubmed: 31732015
J Clin Oncol. 2017 Feb 10;35(5):506-514
pubmed: 28029304
Neuromolecular Med. 2011 Dec;13(4):223-50
pubmed: 21901428
Behav Brain Res. 2008 Jan 25;186(2):168-75
pubmed: 17854921
Neuroimage Clin. 2018 Jul 12;20:110-118
pubmed: 30094161
Lancet Oncol. 2011 Jul;12(7):703-8
pubmed: 21354373
BMC Neurol. 2012 May 28;12:28
pubmed: 22632066
Breast Cancer Res Treat. 2010 Oct;123(3):819-28
pubmed: 20690040
Sensors (Basel). 2013 Mar 06;13(3):3169-203
pubmed: 23467031
J Neurosci. 2018 Mar 14;38(11):2809-2817
pubmed: 29440553
Nat Rev Cancer. 2007 Mar;7(3):192-201
pubmed: 17318212
Front Hum Neurosci. 2017 Nov 15;11:555
pubmed: 29187817
J Clin Oncol. 2018 Oct 3;:JCO1800140
pubmed: 30281396
Rev Neurosci. 2019 Dec 18;31(1):1-57
pubmed: 31194693
J Clin Oncol. 2018 Sep 21;:JCO2018786624
pubmed: 30240328
Palliat Support Care. 2007 Sep;5(3):273-80
pubmed: 17969831
Brain Imaging Behav. 2018 Feb;12(1):64-77
pubmed: 28102529
Springerplus. 2014 Aug 19;3:444
pubmed: 25184110
Arch Clin Neuropsychol. 2007 Jan;22(1):15-24
pubmed: 17142007
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Brain Behav Immun. 2013 Mar;30 Suppl:S117-25
pubmed: 22613170
Neuroimage Clin. 2017 Mar 16;14:685-691
pubmed: 28377882
Womens Health (Lond). 2009 Sep;5(5):503-16
pubmed: 19702450
Cancer. 2007 Jan 1;109(1):146-56
pubmed: 17131349
Health Psychol. 2014 Mar;33(3):222-31
pubmed: 23914817
Innov Clin Neurosci. 2018 Feb 1;15(1-2):36-44
pubmed: 29497579
Clin Neuropsychol. 2006 Feb;20(1):76-89
pubmed: 16410227
CA Cancer J Clin. 2015 Mar;65(2):123-38
pubmed: 25483452
Int Rev Psychiatry. 2014 Feb;26(1):102-13
pubmed: 24716504
Neuropsychol Rev. 2020 Sep;30(3):287-309
pubmed: 32607817
Oncologist. 2008 Dec;13(12):1285-95
pubmed: 19019972